NDAORALFOR SOLUTION
Approved
Dec 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HELICOSOL (Urea C-13) is an oral diagnostic agent supplied as a powder for solution, used in breath tests to detect Helicobacter pylori infection in the gastrointestinal tract. It is a non-invasive diagnostic tool that leverages isotope labeling to identify active H. pylori colonization. The drug does not treat the infection but enables clinical diagnosis to guide treatment decisions.
LOE Approaching
Product is approaching end-of-life with minimal linked job openings, indicating a small, mature brand team likely focused on managed decline rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
HELICOSOL offers minimal career growth potential with zero linked job openings and a product in late-stage decline. Roles on this brand are typically smaller, focused on defending market share and managing profitability rather than innovation or expansion.
Brand ManagerSales Representative
Worked on HELICOSOL at GT Metabolic Solutions? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.